Want to see MDLN full AI Analyst Report?
MDLN Stock Chart & Stats
$36.30
$0.46(1.31%)
At close: 4:00 PM EDT
$36.30
$0.46(1.31%)
Day’s Range― - ―
52-Week Range$31.63 - $50.88
Previous Close$35.5
Volume6.63M
Average Volume (3M)7.38M
Market Cap
$42.22B
Enterprise Value$50.93K
Total Cash (Recent Filing)$2.68B
Total Debt (Recent Filing)$12.64B
Price to Earnings (P/E)38.4
Beta0.87
Next Earnings
Nov 10, 2026EPS Estimate
0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.86
Shares Outstanding877,351,200
10 Day Avg. Volume5,803,856
30 Day Avg. Volume7,376,716
Financial Highlights & Ratios
PEG Ratio-4.96
Price to Book (P/B)3.18
Price to Sales (P/S)1.20
P/FCF Ratio26.29
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$45.29Price Target Upside24.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
EPS Forecast (FY)1.49
Revenue Forecast (FY)$31.23B
Bulls Say, Bears Say
Bulls Say
Strong Organic GrowthSustained double-digit sales growth indicates broad customer demand and effective commercial execution, rather than reliance on a single short-term catalyst. Continued expansion increases operating scale, strengthens Medline’s market position, and supports investment in products and distribution capacity.
Solid Cash Generation And Improving LeverageStrong free cash flow provides internal funding for capital investment, customer implementations, and remediation costs while reducing dependence on external financing. Lower net leverage also improves financial flexibility and makes the balance sheet more resilient as the company pursues growth.
Customer Wins Support Durable ExpansionA substantial pipeline of new customer commitments supports future revenue visibility and expands Medline’s presence across acute, physician-office, laboratory, and post-acute channels. These wins can deepen scale advantages and create recurring demand as implementations mature.
Bears Say
Lower EBITDA Outlook Despite Sales GrowthThe reduced earnings outlook shows that revenue growth is not fully converting into profit, weakening near-term operating leverage. Margin pressure from several internal factors may persist beyond the current period, limiting earnings expansion and reducing the benefit of otherwise strong sales momentum.
Quality Remediation Raises Structural CostsOngoing quality remediation can absorb management attention, increase compliance spending, and delay product reintroduction. Because the program is global and FDA-engaged, its effects may extend across multiple periods, weighing on margins and slowing the recovery of affected product revenue.
Higher Leverage Limits Financial FlexibilityMeaningful leverage reduces flexibility if operating conditions tighten and can constrain the funds available for acquisitions, capacity expansion, or other strategic priorities. Declining equity alongside higher debt-to-equity increases the importance of maintaining steady cash generation and earnings.
Medline News
MDLN FAQ
What was Medline’s price range in the past 12 months?
Medline lowest stock price was $31.63 and its highest was $50.88 in the past 12 months.
What is Medline’s market cap?
Medline’s market cap is $42.22B.
When is Medline’s upcoming earnings report date?
Medline’s upcoming earnings report date is Nov 10, 2026 which is in 53 days.
How were Medline’s earnings last quarter?
Medline released its earnings results on Aug 05, 2026. The company reported $0.5 earnings per share for the quarter, beating the consensus estimate of $0.352 by $0.148.
Is Medline overvalued?
According to Wall Street analysts Medline’s price is currently Undervalued.
Does Medline pay dividends?
Medline does not currently pay dividends.
What is Medline’s EPS estimate?
Medline’s EPS estimate is 0.35.
How many shares outstanding does Medline have?
Medline has 877,351,200 shares outstanding.
What happened to Medline’s price movement after its last earnings report?
Medline reported an EPS of $0.5 in its last earnings report, beating expectations of $0.352. Following the earnings report the stock price went down -12.785%.
Which hedge fund is a major shareholder of Medline?
Currently, no hedge funds are holding shares in MDLN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Medline Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$45.29 (24.78% Upside)
$45.29 (24.78% Upside)
Blogger Sentiment
Bullish
MDLN Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 12.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $158.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.4%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
8.02%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Medline
Medline Inc. is a global manufacturer of medical and surgical products, catering to a broad spectrum of healthcare providers. Their clientele includes hospitals, surgical centers, physician practices, post-acute care facilities, and nursing homes, both domestically and worldwide. The company's operations are divided into two primary divisions: the Medline Brand and Supply Chain Solutions. The Medline Brand division focuses on the production and sourcing of its proprietary medical products, categorized into three key areas: Within Frontline Care, Medline provides a wide array of patient-facing medical and surgical items. This encompasses essentials like wound care treatments, examination gloves, skin and incontinence products, sanitation supplies, various textiles, hand sanitizers, durable medical equipment (DME), patient-specific plastic goods, and decolonization and infection control solutions. The Surgical Solutions category delivers comprehensive product lines for operating rooms and perioperative settings. Offerings range from surgical procedure trays, drapes, and gowns to personal protective equipment (PPE), sterile wraps, various surgical instruments, specialized surgeon's gloves, complete procedure kits, and orthopedic implants. Finally, Laboratory and Diagnostics supplies critical solutions for clinical testing and analysis. This includes point-of-care testing devices, analytical instruments, laboratory consumables, advanced diagnostic equipment, vital signs monitoring systems, and products for anatomic pathology and phlebotomy. The Supply Chain Solutions segment is responsible for sourcing and distributing a diverse portfolio of third-party products, including those from well-known national brands. Beyond distribution, this segment offers comprehensive logistics and supply chain optimization services to clients both domestically and internationally. These optimization services encompass strategic consulting, outsourced management of warehousing and technology, specialized "put-away-ready" packaging, third-party logistics (3PL), inventory rationalization strategies, and efficient route planning. Established in 1966, Medline Inc. maintains its headquarters in Northfield, Illinois.
MDLN Company Deck
MDLN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a balanced picture: strong top-line momentum (12% Q2 sales growth), segment wins, improved sales guidance and robust cash generation are significant positives. However, meaningful margin pressure—driving a lower adjusted EBITDA outlook—stems from the Tracy distribution center fire, ongoing quality remediation, retail softness, and increased operating/COGS pressures. The company is investing to support long-term growth and expects some costs to be transitory, but a sizable portion will increase the baseline cost structure.View all MDLN earnings summariesMDLN Stock 12 Month Forecast
Average Price Target
$45.29
▲(24.78% Upside)
Technical Analysis
Baxter International
―
Becton Dickinson
―
ICU Medical
―
Merit Medical Systems
―
Teleflex
―